Showing results (121-130 of 202) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancerAdam Brufsky, W Graydon Harker, J Thaddeus Beck, et al.
Breast Cancer Research and Treatment|December 4, 2008
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumabAruna Mani, Julie Roda, Donn Young, et al.
The Oncologist|May 7, 2026
Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancerAdam Brufsky, Rachel M Layman, Xianchen Liu, et al.
Current Oncology (Toronto, Ont.)|March 26, 2025
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast CancerHope S Rugo, Aditya Bardia, Peter Schmid, et al.
Frontiers in Oncology|September 2, 2025
Real-world effectiveness and safety of CDK4/6i in elderly and BIPOC patients with HR+/HER2- advanced/metastatic breast cancer: an updated systematic literature reviewNadia Harbeck, Adam Brufsky, Chloe Grace Rose, et al.
Breast Cancer Research : BCR|March 25, 2021
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practiceAngela DeMichele, Massimo Cristofanilli, Adam Brufsky, et al.
Frontiers in Oncology|March 25, 2025
Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2- advanced/metastatic breast cancer: updated systematic reviewNadia Harbeck, Adam Brufsky, Chloe Grace Rose, et al.
Breast Cancer (Dove Medical Press)|April 21, 2017
An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivorsTheresa A Koleck, Catherine M Bender, Beth Z Clark, et al.
Breast (Edinburgh, Scotland)|April 8, 2026
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practiceHope S Rugo, Adam Brufsky, Rachel M Layman, et al.
Bone|March 29, 2016
Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trialChaithra Prasad, Susan L Greenspan, Karen T Vujevich, et al.
Pageof 21